Clinical trials: Metformin
Type 2 Diabetes Mellitus
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02367066
- Testing
- AR-C165395XX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin…
- Trial name
- NCT01462266
- Testing
- Sitagliptin, Insulin Glargine, Metformin
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or…
- Trial name
- NCT01232946
- Testing
- liraglutide, insulin detemir, liraglutide plus insulin detemir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type II
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has sponsored a consortium of investigators to conduct a clinical treatment trial, Treatment Options for type…
- Trial name
- TODAY (NCT00081328)
- Testing
- Metformin, Rosiglitazone, Lifestyle Program
- Where
- 16 sites in United States
- Volunteers
- 699 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318109
- Testing
- Alogliptin and metformin, Metformin
- Volunteers
- 288 people
- Sponsor
- Takeda
Head and Neck Squamous Cell Carcinoma
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.
- Trial name
- NCT04414540
- Testing
- Metformin Extended Release Oral Tablet, Pembrolizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Trisha Wise-Draper
Bipolar Disorder
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
A prospective, large, pragmatic, randomized trial to study the impact of METFORMIN and healthy lifestyle intervention (LIFE) vs.
- Trial name
- MOBILITY (NCT02515773)
- Testing
- Metformin, healthy lifestyle intervention (LIFE)
- Where
- 29 sites in United States
- Volunteers
- 1,565 people
- Sponsor
- Melissa Delbello
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010) in comparison to placebo, as an add-on treatment to metformin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GetGoal-M-Asia (NCT01169779)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 35 sites in China, Hong Kong and 2 more
- Volunteers
- 391 people
- Sponsor
- Sanofi
Type 1 Diabetes
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Diabetes is increasingly common among youth, forecasting early complications. Type 1 (T1D) cause early heart disease, shortening lifespan despite modern improvements in control of blood sugars and other risk factors for heart…
- Trial name
- EMERALD (NCT01808690)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Comprehensive Add on Study in Japan
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control…
- Trial name
- NCT01204294
- Testing
- Linagliptin, Metformin
- Where
- 43 sites in Japan
- Volunteers
- 574 people
- Sponsor
- Boehringer Ingelheim
Healthy
Metformin ER 750 mg Tablets, Fasting
The objective of this study is to compare the rate and extent of absorption of metformin from a test formulation of Metformin ER 750 mg Tablets versus the reference Glucophage® XR 750 mg Tablets under fasting conditions.
- Trial name
- NCT00834743
- Testing
- Glucophage® XR 750 mg Tablets, Metformin ER 750 mg Tablets
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic…
- Trial name
- LEAD-6 (NCT00518882)
- Testing
- liraglutide, exenatide
- Where
- 125 sites in United States, Austria and 14 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
- Trial name
- PRONTO-T2D (NCT03214380)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 141 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics
The purpose of this study is to learn about a drug-drug interaction. When two medications are taken together at the same time, one medication may change the activity of the other medication in the body - this is called a…
- Trial name
- NCT03655301
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Metformin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy
- Trial name
- NCT04465877
- Testing
- JTT-662
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Shionogi Inc.
Diabetes Mellitus, Type 2, Hyperglycemia
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01719003
- Testing
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd
- Where
- 190 sites in United States, Brazil and 19 more
- Volunteers
- 1,413 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of LY2409021 in Patients With Type 2 Diabetes
LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week…
- Trial name
- NCT01241448
- Testing
- LY2409021
- Where
- 40 sites in United States, Germany and 5 more
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2…
- Trial name
- EAGLE (NCT01117350)
- Testing
- Insulin glargine, Liraglutide, Metformin
- Where
- 136 sites in United States, Austria and 15 more
- Volunteers
- 978 people
- Sponsor
- Sanofi